Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis. - Wikidata - awgldk - TriplyDB

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

http://www.wikidata.org/entity/Q37287648

about

Pseudomonas Endocarditis with an unstable phenotype: the challenges of isolate characterization and Carbapenem stewardship with a partial review of the literature.Increased Expression of Plasma-Induced ABCC1 mRNA in Cystic Fibrosis.Characterization and Genomic Analyses of Podovirus TC6: Establishment of Genus

P2860

Q40073768-3335D9D7-C436-40F4-8FF5-0CD1F1B388EA Q41574129-DFF5C912-CBC9-4B21-846C-E9A48F7542D8 Q58556357-218BA68D-23F9-4112-B678-1BBDB627C500

P2860

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

http://www.wikidata.org/entity/Q37287648

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

@en

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

@nl

type

label

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

@en

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

@nl

prefLabel

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

@en

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

@nl

P1433

Q37287648-8CF865C7-989E-4DDD-90CC-FF12545193CB

P1476

Q37287648-AD967089-0852-47D9-B577-7587330CB912

P2093

Q37287648-020AF156-FE2F-4FD7-979C-810690263558

Q37287648-9C131EFE-BE9D-4283-AB17-5B0543CD0F7C

Q37287648-B65F707A-C815-4A6A-B878-E8612F3E51F4

Q37287648-D2CB5477-619C-450A-B6E3-EDCE7B936EDE

Q37287648-F58F12C3-06C1-4960-A930-CCF7955ADA2D

P2860

Q37287648-4F2566B3-521D-4849-B80A-BBBD864F9760

Q37287648-8F5A5642-7DF5-4CA5-9789-C6CF8DC59C45

Q37287648-B27BDC11-F7EF-4277-B467-307779EE08B9

Q37287648-B58B8EA7-D0A3-436B-8442-DF3157249C41

Q37287648-B58EAF80-3417-4956-8521-18714EEAA620

Q37287648-B5C79F15-0EAF-4EFF-A126-55F5FBD772EF

Q37287648-C29F802E-36E4-47DB-84D8-08B3E41C12DC

Q37287648-CA1D18A4-17E6-4E89-9738-328F0C2BC7D9

Q37287648-D184F8CC-119D-4A3F-83BC-25CFC48C17A8

Q37287648-E99B90D9-3F02-4264-88D5-B6492AC3627D

P304

Q37287648-D46E04E1-A6C1-409A-A870-0FC5EB953270

P31

Q37287648-5058DAEA-249B-4493-B894-DC696B217652

Q37287648-87720f45-7b31-46ed-9450-54ced817b7ca

P356

Q37287648-709B0E25-A934-4DC2-802E-07F8C22D8F29

P407

Q37287648-26BCFFAD-FABB-4A28-B348-ACCD737CD446

P433

Q37287648-4DF910AE-3BD8-43D6-B469-E5FD86D908A0

P478

Q37287648-16AE7B0C-BC07-4320-A3C8-7BA80E16E6FC

P50

Q37287648-71517480-188F-4BFB-9094-12686E0C4D21

Q37287648-D0457FC1-CF1A-4E5C-8C6E-743EC91A91AF

P577

Q37287648-ACD15DA2-5AD4-4D2D-B791-5CB39F3BFD1E

P698

Q37287648-B30C767E-32A3-4659-AB5D-D1F3C637AB38

P921

Q37287648-6CD1F2B8-8662-4607-833A-9E8B08E2728B

Q37287648-7ECA38DC-AB57-498D-8CEF-4206BB23B664

Q37287648-C490303C-5311-4177-A8BD-B308BBBC8538

P932

Q37287648-9800CE24-C0CB-47CC-8083-97C7E0E316FA

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis

@en

P2093

David P Nicolau

http://www.w3.org/2001/XMLSchema#string

Frank Zhu

http://www.w3.org/2001/XMLSchema#string

Jocelyn Y Ang

http://www.w3.org/2001/XMLSchema#string

Michael J Satlin

http://www.w3.org/2001/XMLSchema#string

Nahed Abdel-Haq

http://www.w3.org/2001/XMLSchema#string

P2860

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination

Pseudomonas aeruginosa: all roads lead to resistance

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia

Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations

Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.

Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients.

Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.

Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore

P304

5627-5630

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00705-16

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27664282

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

Pseudomonas aeruginosa

multiple drug resistance

P932

5038228

http://www.w3.org/2001/XMLSchema#string